Akademik Veri Yönetim Sistemi
1st International Gazi Pharma Symposium Series (GPSS-2015), Antalya, Türkiye, 12 - 15 Kasım 2015, ss.182
Alzheimer’s disease is an age-related neurodegenative disorder which affects more than 35
million people worldwide and involves in 60-80% of the dementia cases [1], [2]. Neurotransmitter
acetylcholin’s deficiency in central nervous system causes cognitive impairement in Alzheimer
patients. The cholinergic approach for the therapy of this disease is using either an agonist or
AChE (acetylcholinesterase) inhibitor to increase the cholinergic function [3]. In our previous study,
a group of N-{2-[4-(1H-benzimidazole-2-yl)phenoxy]ethyl}substituted amine derivatives were
synthesized and evaluated for their inhibitor activity against AChE [4]. Most of the compounds
were exhibited good inhibition. Also we known that, an important number of studies report the
activity of Mannich bases as AChE inhibitors [5]. In this study, a series of novel ‘mannich bases of
2-phenolsubstitutedbenzimidazole’ derivatives (Fig 1) were synthesized and characterized by 1
H
NMR, mass spectral studies and elemental analysis. The compounds evaluated for the inhibition
activity against AChE by using Ellman’s method [6]. The final compounds exhibited from moderate
to good activities to the AChE enzyme compared to the standart drug.